Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Nov 12 | 2024AZ, Altimmune, and Scholar Rock Q3 ’24 Earnings; New Ph2 Lilly Trial ObservedPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Topics Nov 11 | 2024November CHMP AgendaPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics Nov 08 | 2024Insulet, Senseonics, Akero, Skye, MannKind, and Xeris Q3 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Nov 06 | 2024Novo Q3 '24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Nov 01 | 2024Novo Semaglutide MASH Data; Abbott GLP-1RA Adherence Study; Alnylam and Regeneron Q3 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 30 | 2024QW Icodec CRL Information; Beta Bionics Launches Libre 3+ Integration; O5 iOS App US Launch; Zealand Obesity TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 30 | 2024Lilly Q3 ’24 Earnings CallPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 28 | 2024Abbott and Tidepool Partnership; New Retatrutide Obesity Trial; Apple Prediabetes AppPurchase Blast
1 2 3 95

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.